GeekWire

UW biotech spinout raises $5M to develop gene therapy system for muscular dystrophy

From left: Myosana CEO Matthew Lumley, with co-founders Stanley Froehner and Nick Whitehead. (Myosana and UW Photos) The news: Myosana Therapeutics, a Seattle startup developing gene therapy ...
Business Wire

Satellos Discloses Drug Target and Provides Development Update on Duchenne Muscular Dystrophy Program

TORONTO--(BUSINESS WIRE)--Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSXV: MSCL) (OTCQB: MSCLF), a publicly traded biotech company developing new small molecule therapeutic approaches to ...
Morningstar

Form Bio and Cure Rare Disease Partner to Accelerate Genetic Medicine Development, Advancing CRD's Duchenne Muscular Dystrophy Program

Partnership leverages AI-powered genome design to optimize AAV constructs, accelerate lead candidate selection, and improve drug substance manufacturability for rare and ultra-rare neuromuscular ...
Business Wire

Satellos Announces Formation of Clinical Advisory Board to Support Advancing SAT-3247 in Clinical Trial Development for Duchenne Muscular Dystrophy

TORONTO--(BUSINESS WIRE)--Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSX: MSCL, OTCQB: MSCLF), a public biotech company developing new small molecule therapeutic approaches to improve the ...
Mena FN

Spinal Muscular Atrophy Pipeline 2025: Comprehensive Analysis Of Emerging Therapies, Clinical Trials, Drug Development, And Future Treatment Opportunities

DelveInsight's “Spinal Muscular Atrophy Pipeline Insight 2025” report provides comprehensive insights about 18+ companies and 20+ pipeline drugs in the Spinal Muscular Atrophy pipeline landscape. It ...
BMJ

Contribution of Physical Development and Muscular Strength to the Motor Performance Capacity of 7 to 12 Year Old Boys

The contribution of selected physical development and muscular strength measures to general motor performance capacity was investigated in 55 seven to twelve year old boys. The physical development ...